CD44 and prostate cancer: Previously in prostate cancer (PCa) cells, 4-MU was found to inhibit HA synthesis and receptor–mediated signaling, while addition of HA to PC3-ML prostate cancer cells blocked 4-MU-mediated downregulation of CD44, pAKT, and PI3K activity32.